



PRESS RELEASE

## Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US

***Bengaluru, India and Iselin, NJ, USA. December- 28, 2020***

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced the launch of Tacrolimus capsules in the US.

Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

The launch of Tacrolimus capsules, following an approval from the US FDA in November 2020, underscores Biocon's relentless pursuit of its mission to make affordable healthcare accessible.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said: "The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients."

### **About Biocon Limited:**

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

**Disclaimer:** This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.

For Media Information	
<b>Media Relations</b> BIOCON LIMITED Calvin Printer +91 80 2808 2132 Email: calvin.printer@biocon.com	<b>Investor Relations</b> BIOCON LIMITED Ankit Gupta +91 80 2808 2040 Email: ankit.gupta@biocon.com